drugset / Trial / NCT02182167

A Trial Of Intravenous N-Acetylcysteine In The Management Of Antituberculous Drug-Induced Hepatitis

NCT02182167

RandomizedSingle-groupQuadruple-blindTreatment

Summary

We will conduct a randomized placebo controlled trial to determine whether administration of intravenous (IV) NAC to participants with TB DIH, in dosages similar to that used in paracetamol poisoning, can improve recovery from hepatotoxicity.

Timeline

Start
2014-05
Primary completion
2019-02
Completion
2019-02

Drugs

EvaluationDrugModalityDoseRoute
Subject N-acetylcysteine Small molecule 100 mg/kg Intravenous